

Wright Medical Group N.V.
Reconciliation of Net Sales to Non-GAAP Combined Pro Forma Net Sales
(unaudited)

	Three months ended		
	December 27, 2015		
	Net Sales As Reported	Legacy Tornier stub period (September 28, 2015 - September 30, 2015) ⁽¹⁾	Non-GAAP Combined Pro Forma Net Sales
U.S.			
Lower extremities	\$ 58,819	\$ 279	\$ 59,098
Upper extremities	47,053	1,773	48,826
Biologics	15,971	66	16,037
Sports med & other	1,830	4	1,834
Total extremities & biologics	123,673	2,122	125,795
Large joint	18	—	18
Total U.S.	\$ 123,691	\$ 2,122	\$ 125,813
International			
Lower extremities	\$ 15,887	\$ 152	\$ 16,039
Upper extremities	19,066	1,260	20,326
Biologics	4,582	13	4,595
Sports med & other	3,625	132	3,757
Total extremities & biologics	43,160	1,557	44,717
Large joint	10,117	753	10,870
Total International	\$ 53,277	\$ 2,310	\$ 55,587
Global			
Lower extremities	\$ 74,706	\$ 431	\$ 75,137
Upper extremities	66,119	3,033	69,152
Biologics	20,553	79	20,632
Sports med & other	5,455	136	5,591
Total extremities & biologics	166,833	3,679	170,512
Large joint	10,135	753	10,888
Total sales	\$ 176,968	\$ 4,432	\$ 181,400

⁽¹⁾ To add revenues from Legacy Tornier's fourth quarter for the period prior to the merger closing date when operations became consolidated.

Wright Medical Group N.V.
Reconciliation of Net Sales to Non-GAAP Combined Pro Forma Net Sales
(unaudited)

	Twelve months ended				
	December 27, 2015				
	Net Sales As Reported	Legacy Tornier N.V. standalone nine months ended September 27, 2015 ⁽¹⁾	Legacy Tornier Net Sales Divested ⁽²⁾	Legacy Tornier stub period (September 28, 2015 - September 30, 2015) ⁽³⁾	Non-GAAP Combined Pro Forma Net Sales
U.S.					
Lower extremities	187,096	29,637	(9,733)	279	207,279
Upper extremities	58,756	115,846	—	1,773	176,375
Biologics	50,583	1,290	—	66	51,939
Sports med & other	3,388	5,021	—	4	8,413
Total extremities & biologics	299,823	151,794	(9,733)	2,122	444,006
Large joint	18	119	—	—	137
Total U.S.	\$ 299,841	\$ 151,913	\$ (9,733)	\$ 2,122	\$ 444,143
International					
Lower extremities	51,200	7,402	—	152	58,754
Upper extremities	24,789	51,293	—	1,260	77,342
Biologics	19,652	357	—	13	20,022
Sports med & other	9,862	5,372	—	132	15,366
Total extremities & biologics	105,503	64,424	—	1,557	171,484
Large joint	10,117	29,921	—	753	40,791
Total International	\$ 115,620	\$ 94,345	\$ —	\$ 2,310	\$ 212,275
Global					
Lower extremities	238,296	37,039	(9,733)	431	266,033
Upper extremities	83,545	167,139	—	3,033	253,717
Biologics	70,235	1,647	—	79	71,961
Sports med & other	13,250	10,393	—	136	23,779
Total extremities & biologics	405,326	216,218	(9,733)	3,679	615,490
Large joint	10,135	30,040	—	753	40,928
Total sales	\$ 415,461	\$ 246,258	\$ (9,733)	\$ 4,432	\$ 656,418

(1) Legacy Tornier product line sales have been recast to reflect the reclassification of cement, instruments and freight from the historical Tornier product line "Large Joints and Other" to the product line associated with those revenues that will be utilized for future revenue reporting.

(2) To reduce from Tornier's historical sales the U.S. sales associated with Tornier's Salto Talaris and Salto XT ankle replacement products and silastic toe replacement products.

(3) To add revenues from Legacy Tornier's fourth quarter for the period prior to the merger closing date when operations became consolidated.

Wright Medical Group N.V.
Reconciliation of Total Extremities & Biologics Net Sales to
Adjusted Combined Pro Forma Total Extremities & Biologics Net Sales
Average Sales per Day
(unaudited)

	Three months ended					
	December 27, 2015			December 31, 2014		
	U.S.	International	Global	U.S.	International	Global
Legacy Wright	\$ 72,121	\$ 21,444	\$ 93,565	\$ 62,486	\$ 20,808	\$ 83,294
Legacy Tornier	51,552	21,716	73,268	N/A	N/A	N/A
Net sales, as reported	\$ 123,673	\$ 43,160	\$ 166,833	\$ 62,486	\$ 20,808	\$ 83,294
Standalone Tornier N.V. recast ⁽¹⁾	—	—	—	53,607	24,588	78,195
Revenues divested ⁽²⁾	—	—	—	(4,214)	—	(4,214)
Legacy Tornier stub period (September 28, 2015 - September 30, 2015) ⁽³⁾	2,122	1,557	3,679	—	—	—
Legacy Tornier impact of FX ⁽⁴⁾	—	2,951	2,951	—	—	—
Pro forma legacy Tornier, excluding the impact of FX	\$ 53,674	\$ 26,224	\$ 79,898	\$ 49,393	\$ 24,588	\$ 73,981
Legacy Wright impact of revenue recognition ⁽⁵⁾	(2,994)	—	(2,994)	—	—	—
Legacy Wright impact of FX ⁽⁴⁾	—	2,155	2,155	—	—	—
Adjusted legacy Wright, excluding the impact of FX	\$ 69,127	\$ 23,599	\$ 92,726	\$ 62,486	\$ 20,808	\$ 83,294
Legacy Tornier selling days	61	65		61	65	
Legacy Wright selling days	58	62		62	66	
Adjusted combined pro forma average sales per day, excluding the impact of FX ⁽⁶⁾	\$ 2,072	\$ 784	\$ 2,856	\$ 1,818	\$ 694	\$ 2,512
Adjusted pro forma average sales per day constant currency growth % ⁽⁷⁾	14.0%	13.0%	13.7%			

- (1) Legacy Tornier's product line sales have been recast to reflect the reclassification of cement, instruments and freight from the historical Tornier product line "Large Joints and Other" to the product line associated with those revenues that will be utilized for future revenue reporting.
- (2) To reduce from Legacy Tornier's historical sales the U.S. sales associated with Tornier's Salto Talaris and Salto XT ankle replacement products and silastic toe replacement products.
- (3) To add revenues from Legacy Tornier's fourth quarter for the period prior to Merger closing date when operations became consolidated.
- (4) The impact of FX on net sales is calculated by translating current year results at prior year average foreign currency exchange rates.
- (5) Legacy Wright recognized approximately \$3 million during the fourth quarter of 2015, as result of conforming its methodology for revenue recognition with Legacy Tornier.
- (6) Legacy Wright and Legacy Tornier have historically operated on different fiscal periods. In order to calculate Pro Forma sales growth, we have calculated average sales per day ("ASPD") based on the respective legacy company and the associated geographic region, then added the legacy company ASPD together.
[Example: Q4 2015 Pro Forma Legacy Tornier U.S. Sales / Legacy Tornier U.S. Selling Days = \$880K. Q4 2015 Adjusted Legacy Wright U.S. Sales / Legacy Wright U.S. Selling Days = \$1,191K. Adjusted Pro Forma Combined Average Sales per Day = \$2,072K]
- (7) Reflects growth of Pro Forma ASPD over comparable period. International Sales and Global Sales growth excludes the impact of FX (see Note 4).

Wright Medical Group N.V.

Reconciliation of Non-GAAP Combined Pro Forma Cash Earnings Per Share to Net Loss from Continuing Operations

(in thousands, except per share data--unaudited)

	Three Months Ended	Twelve Months Ended
	December 27, 2015	December 27, 2015
Net loss from continuing operations, as reported	\$ (92,155)	\$ (238,360)
Standalone Tornier N.V. nine months ended September 27, 2015	—	(25,253)
Impact of divested products ⁽¹⁾	—	(5,414)
Impact of purchase accounting adjustments ⁽²⁾	—	(2,919)
Impact of legacy Tornier stub period (September 28, 2015 - September 30, 2015) ⁽³⁾	2,882	2,882
Non-GAAP combined pro forma net loss from continuing operations	\$ (89,273)	\$ (269,064)
Other reconciling items:		
Inventory step-up amortization	11,377	11,446
Distributor conversions and non-competes	—	65
Non-cash interest expense on 2017 & 2020 convertible notes	6,910	24,767
Write-off of unamortized debt discount and deferred financing fees	—	25,101
Derivatives mark-to-market adjustments	2,257	(9,764)
Due diligence, Transaction and transition costs	39,155	82,195
Share-based compensation acceleration	14,190	14,190
CVR mark-to-market adjustments	(280)	(7,630)
Contingent consideration fair value adjustment	—	155
Standalone Tornier N.V. transaction and transition costs	—	8,860
Standalone Tornier N.V. instrument use tax refund	—	(2,000)
Tax effect of reconciling items	(1,827)	(1,854)
Non-GAAP combined pro forma net loss from continuing operations, as adjusted	\$ (17,491)	\$ (123,533)
Add back amortization of intangible assets	9,181	16,856
Add back Tornier N.V. amortization nine months ended September 27, 2015	—	12,057
Non-GAAP combined pro forma cash earnings	\$ (8,310)	\$ (94,620)
Pro forma weighted-average basic shares outstanding	102,659	101,959
Non-GAAP combined pro forma cash earnings per share	\$ (0.08)	\$ (0.93)

⁽¹⁾ To reduce from Legacy Tornier's historical results the net income impact of the U.S. sales associated with Tornier's Salto Talaris and Salto XT ankle replacement products and silastic toe replacement products.

⁽²⁾ To reflect the pro forma impact of preliminary purchase accounting adjustments for estimated depreciation, amortization, interest and taxes associated with the preliminary purchase price allocation identified as part of Wright Medical Group N.V.'s Form 8-K/A filed on November 17, 2015.

⁽³⁾ To add net income from Legacy Tornier's fourth quarter for the period prior to Merger closing date when operations became consolidated.

Wright Medical Group N.V.

Reconciliation of Non-GAAP Combined Pro Forma Adjusted EBITDA to Net Loss from Continuing Operations

(in thousands, except per share data--unaudited)

	Three Months Ended	Twelve Months Ended		
	December 27, 2015	December 27, 2015		
	Wright Medical Group N.V.	Wright Medical Group N.V. (reported)	Standalone legacy Tornier N.V.	Pro forma combined
Net loss from continuing operations	\$ (92,155)	\$ (238,360)	\$ (25,253)	\$ (263,613)
Impact of divested products ⁽¹⁾	—	—	(5,414)	(5,414)
Impact of purchase accounting adjustments ⁽²⁾	—	—	(2,919)	(2,919)
Impact of legacy Tornier stub period (September 28, 2015 - September 30, 2015) ⁽³⁾	2,882	—	2,882	2,882
Non-GAAP combined pro forma net loss from continuing operations	\$ (89,273)	\$ (238,360)	\$ (30,704)	\$ (269,064)
Interest expense, net ⁽⁴⁾	11,565	41,358	1,352	42,710
Benefit (provision) from income taxes ⁽⁴⁾	(4,362)	(3,851)	577	(3,274)
Depreciation ⁽⁴⁾	12,542	29,508	23,702	53,210
Amortization ⁽⁴⁾	9,181	16,922	13,419	30,341
Non-GAAP combined pro forma EBITDA	\$ (60,347)	\$ (154,423)	\$ 8,346	\$ (146,077)
Reconciling items impacting EBITDA:				
Non-cash share-based compensation expense	17,259	24,965	6,512	31,477
Other expense, net	3,489	10,884	262	11,146
Inventory step-up amortization	11,377	11,446	—	11,446
Due diligence, transaction and transition costs	39,155	82,195	8,860	91,055
Instrument use tax refund	—	—	(2,000)	(2,000)
Non-GAAP combined pro forma adjusted EBITDA	\$ 10,933	\$ (24,933)	\$ 21,980	\$ (2,953)

(1) To add net income from Legacy Tornier's fourth quarter for the period prior to Merger closing date when operations became consolidated.

(2) To reflect the pro forma impact of preliminary purchase accounting adjustments for estimated depreciation, amortization, interest and taxes associated with the preliminary purchase price allocation identified as part of Wright Medical Group N.V.'s Form 8-K/A filed on November 17, 2015.

(3) To reduce from Legacy Tornier's historical results the net income impact of the U.S. sales associated with Tornier's Salto Talaris and Salto XT ankle replacement products and silastic toe replacement products.

(4) Amounts for Standalone Legacy Tornier N.V. include estimated depreciation, amortization, interest and taxes associated with the preliminary purchase price allocation (see Note 2).

** In addition to the above reconciliations, the Company has provided reconciliations of non-GAAP combined pro forma financial information on Wright's website at ir.wright.com in the "Financial Information" section (see Wright-Tornier merger – IR Presentation 2-23-2016). **